Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial

Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial

Abstract The optimal adjuvant endocrine therapy for HR-positive/HER2-positive breast cancer patients is unknown. We included in this analysis 784 patients with HR-positive/HER2-positive BC from the randomized ShortHER trial of adjuvant trastuzumab (1 year vs 9 weeks) + chemotherapy. At a median foll...

Full description

Bibliographic Details
Main Authors: Maria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini, Antonio Frassoldati, Roberto Vicini, Sara Balduzzi, Roberto D’amico, Pierfranco Conte, Valentina Guarneri
Format: Article
Language:English
Published: Nature Portfolio 2023-02-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-023-00509-2

Internet

https://doi.org/10.1038/s41523-023-00509-2

Similar Items